A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT)

Author:

Wang Xiaobing1,Zhi Xiuyi2,Yang Zhaogang3,Tian Haimei1,Li Yanfen1,Li Mo1,Zhao Wenya1,Zhang Chao1,Wang Teng1,Liu Jing1,Shen Di4,Zheng Cuining4,Zhao Dan5,Yang Sheng6,Qi Jun4,Xin Hongwu78,Stojadinovic Alexander9,Avital Itzhak10,Lee L. James3,Rao Jianyu1,Zhang Wei1

Affiliation:

1. Tumor Marker Research Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

2. Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, PR China

3. NSF Nanoscale Science and Engineering Center (NSEC), The Ohio State University, Columbus, OH, USA

4. Laboratory of Clinical Biochemistry, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

5. Department of Gynecological Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

6. Department of Medicine, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

7. The First Peoples’ Hospital of Jingzhou City, The First Hospital and Clinical Medical School of Yangtze University, Jingzhou, PR China

8. Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Huber, PR China

9. Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

10. P8-Medicine Ltd, Sussex, DE, USA

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3